Author

C. K. Ng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Genomics· 1 Plant Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 6 Organism:human· 6 Assay:bulk RNA-seq· 5 Research Focus:cell type annotation· 4 Approach:statistical model· 4 Approach:experimental assay· 3 Research Focus:gene regulatory network inference· 3 Assay:whole-exome sequencing· 3

Frequent Co-Authors

S. Piscuoglio· 5 shared M. A. Rubin· 3 shared A. Garofoli· 2 shared C. Ercan· 2 shared J. Gallon· 2 shared M. Bolis· 2 shared M. De Menna· 2 shared M. H. Heim· 2 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

S. Piscuoglio

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules

P. D. Thienger, I. Paassen, X. Yao, P. D. Rubin, M. Lehner, N. Lillis, A. Benjak, S. Shah, A. King-Yung Leung, S. de Brot, A. Naveed, B. Daniel, M. Shi, J. Tremblay, J. Triscott, , M. A. Rubin

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

bioRxiv · Mar 24, 2024Cancer Biology

Proteogenomic characterization of hepatocellular carcinoma

C. K. Ng, E. Dazert, T. Boldanova, M. Coto-Llerena, S. Nuciforo, C. Ercan, A. Suslov, M.-A. Meier, T. Bock, A. Schmidt, S. Ketterer, X. Wang, S. Wieland, M. S. Matter, M. Colombi, , M. H. Heim

This study identifies differentially regulated pathways and candidate driver genes in hepatocellular carcinomas through proteogenomic analysis across clinical stages and etiologies.

bioRxiv · Mar 5, 2021 · PreprintGenomics

LncRNA analyses reveal increased levels of non-coding centromeric transcripts in hepatocellular carcinoma

A. Necsulea, P. Veber, T. Boldanova, C. K. Ng, S. Wieland, M. H. Heim

The paper analyzes lncRNA expression in HCC to identify differentially expressed transcripts and reveals increased non-coding centromeric transcripts in advanced-stage tumors.

bioRxiv · Mar 3, 2021 · PreprintCancer Biology

Patient-derived xenografts and organoids model therapy response in prostate cancer

S. Karkampouna, F. La Manna, M. R. De Filippo, M. Kiener, M. De Menna, E. Zoni, J. Grosjean, I. Klima, A. Garofoli, M. Bolis, J.-P. Theurillat, V. Genitsch, D. Keller, T. Booij, C. Stirnimann, , M. Kruithof-de Julio

This study develops a patient-derived xenograft (PDX) model of prostate cancer that mimics disease stages and identifies drug sensitivities in metastatic cases.

Nature Communications · Feb 18, 2021Peer-reviewedCancer Biology

The nitrogen-fixing symbiotic cyanobacterium, Nostoc punctiforme can regulate plant programmed cell death

S. P. Belton, P. F. McCabe, C. K. Ng

This study shows that Nostoc punctiforme can suppress plant programmed cell death via transcriptional reprogramming and provides a transcriptome resource for early symbiotic signaling.

bioRxiv · Aug 13, 2020Plant Biology

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

G. Bianco, M. Coto Llerena, J. Gallon, S. Taha-Mehlitz, V. Kancherla, M. Konantz, S. Srivatsa, H. Montazeri, F. Panebianco, M. De Menna, V. Paradiso, C. Ercan, A. Dahmani, E. Montaudon, N. Beerenwinkel, , S. Piscuoglio

This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.

bioRxiv · May 18, 2020Cancer Biology

The Genomic Landscape of Prostate Cancer Brain Metastases

A. Rodriguez, J. Gallon, D. Akhoundova, S. Maletti, A. Ferguson, J. Cyrta, U. Amstutz, A. Garofoli, V. Paradiso, S. Tomlins, E. Hewer, V. Genitsch, A. Fleischmann, E. J. Rushing, R. Grobholz, , M. A. Rubin

This study identifies genomic alterations in prostate cancer brain metastases, highlighting mutations in NF1 and RICTOR and DNA homologous repair defects as potential drivers.

bioRxiv · May 12, 2020 · PreprintCancer Biology